NM_001099404.2:c.5068G>A
Variant summary
Our verdict is Uncertain significance. The variant received 2 ACMG points: 2P and 0B. PP3_Moderate
The NM_001099404.2(SCN5A):c.5068G>A(p.Asp1690Asn) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000744 in 1,613,936 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Synonymous variant affecting the same amino acid position (i.e. D1690D) has been classified as Likely benign.
Frequency
Consequence
NM_001099404.2 missense
Scores
Clinical Significance
Conservation
Publications
- Brugada syndromeInheritance: AD Classification: DEFINITIVE, SUPPORTIVE Submitted by: ClinGen, Orphanet
- Brugada syndrome 1Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Ambry Genetics, Laboratory for Molecular Medicine, G2P, Genomics England PanelApp, Labcorp Genetics (formerly Invitae)
- dilated cardiomyopathyInheritance: AD Classification: DEFINITIVE Submitted by: ClinGen
- dilated cardiomyopathy 1EInheritance: AD Classification: DEFINITIVE, STRONG Submitted by: G2P, Labcorp Genetics (formerly Invitae), Ambry Genetics
- familial long QT syndromeInheritance: AD Classification: DEFINITIVE Submitted by: ClinGen
- long QT syndrome 3Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Ambry Genetics, Labcorp Genetics (formerly Invitae), G2P
- sick sinus syndrome 1Inheritance: AD, AR Classification: STRONG, LIMITED Submitted by: Labcorp Genetics (formerly Invitae)
- progressive familial heart block, type 1AInheritance: SD, AD Classification: STRONG, MODERATE Submitted by: Ambry Genetics, Genomics England PanelApp
- atrial standstillInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- familial atrial fibrillationInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- familial isolated dilated cardiomyopathyInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- familial sick sinus syndromeInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- paroxysmal familial ventricular fibrillationInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- progressive familial heart blockInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- arrhythmogenic right ventricular cardiomyopathyInheritance: AD Classification: LIMITED Submitted by: ClinGen
- catecholaminergic polymorphic ventricular tachycardiaInheritance: AD Classification: NO_KNOWN Submitted by: ClinGen
- short QT syndromeInheritance: AD Classification: NO_KNOWN Submitted by: ClinGen
Genome browser will be placed here
ACMG classification
Our verdict: Uncertain_significance. The variant received 2 ACMG points.
Transcripts
RefSeq
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| SCN5A | ENST00000413689.6 | c.5068G>A | p.Asp1690Asn | missense_variant | Exon 28 of 28 | 5 | NM_001099404.2 | ENSP00000410257.1 | ||
| SCN5A | ENST00000423572.7 | c.5065G>A | p.Asp1689Asn | missense_variant | Exon 28 of 28 | 1 | NM_000335.5 | ENSP00000398266.2 |
Frequencies
GnomAD3 genomes AF: 0.0000132 AC: 2AN: 152046Hom.: 0 Cov.: 31 show subpopulations
GnomAD2 exomes AF: 0.00000398 AC: 1AN: 251488 AF XY: 0.00 show subpopulations
GnomAD4 exome AF: 0.00000684 AC: 10AN: 1461890Hom.: 0 Cov.: 34 AF XY: 0.00000688 AC XY: 5AN XY: 727244 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.0000132 AC: 2AN: 152046Hom.: 0 Cov.: 31 AF XY: 0.0000269 AC XY: 2AN XY: 74242 show subpopulations
ClinVar
Submissions by phenotype
not specified Uncertain:2
Variant identified in a genome or exome case(s) and assessed due to predicted null impact of the variant or pathogenic assertions in the literature or databases. Disclaimer: This variant has not undergone full assessment. The following are preliminary notes: Functional study suggests pathogenicity, but no segs and only 1 proband; Absent from ExAC -
Variant summary: SCN5A c.5068G>A (p.Asp1690Asn) results in a conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 4e-06 in 251488 control chromosomes. c.5068G>A has been reported in the literature in individuals affected with Brugada Syndrome (e.g. Nunez_2013). In one family, this variant does not co-segregate with Brugada Syndrome (Zeng_2016). Co-occurrence with a pathogenic variant has been reported (TTN c.48868C>T, p.Arg16290X, internal database), providing supporting evidence for a benign role. Three publications report experimental evidence evaluating an impact on protein function and showed that this variant affect SCN5A function (Nunez_2013, Zeng_2016), however, this effect may not associate with BrS clinical phenotype (Pearman_2020). Three clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as VUS. -
not provided Uncertain:2
Not observed at significant frequency in large population cohorts (gnomAD); A published functional study suggests that the p.(D1690N) variant results in loss-of-function phenotype (PMID: 27108952); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 23085483, 30662450, 30203441, 33131149, 34546463, 32268277, 26173111, 27108952) -
This sequence change replaces aspartic acid, which is acidic and polar, with asparagine, which is neutral and polar, at codon 1690 of the SCN5A protein (p.Asp1690Asn). This variant is present in population databases (no rsID available, gnomAD 0.003%). This missense change has been observed in individual(s) with Brugada syndrome (PMID: 23085483, 27108952, 30203441, 32893267, 34546463). This variant is also known as c.4906G>A (p.Asp1636Asn). ClinVar contains an entry for this variant (Variation ID: 403420). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. Experimental studies have shown that this missense change affects SCN5A function (PMID: 23085483, 27108952). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Cardiac arrhythmia Uncertain:2
This missense variant replaces aspartic acid with asparagine at codon 1690 of the SCN5A protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). Functional studies have shown that this variant causes reduced channel trafficking to the plasma membrane, decreased sodium channel current density, positive shift of activation, and slower recovery from inactivation (PMID: 23085483, 23085483, 30232268). This variant has been reported in at least three unrelated individuals affected with Brugada syndrome (PMID: 23085483, 26173111, 27108952, 32268277, 32893267). One of these individuals carried a pathogenic c.3840+1G>A variant in the same gene that could explain the observed phenotype (PMID: 26173111). This variant has been identified in 1/251488 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
This missense variant replaces aspartic acid with asparagine at codon 1690 of the SCN5A protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). Functional studies have shown that this variant causes reduced channel trafficking to the plasma membrane, decreased sodium channel current density, positive shift of activation, and slower recovery from inactivation (PMID: 23085483, 23085483, 30232268). This variant has been reported in at least three unrelated individuals affected with Brugada syndrome (PMID: 23085483, 26173111, 27108952, 32268277, 32893267). One of these individuals carried a pathogenic c.3840+1G>A variant in the same gene that could explain the observed phenotype (PMID: 26173111). This variant has been identified in 1/251488 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
Brugada syndrome 1 Pathogenic:1
ACMG Criteria: PS3, PM1, PP3, PP5; Variant was found in heterozygous state -
Cardiovascular phenotype Uncertain:1
The p.D1690N variant (also known as c.5068G>A), located in coding exon 27 of the SCN5A gene, results from a G to A substitution at nucleotide position 5068. The aspartic acid at codon 1690 is replaced by asparagine, an amino acid with highly similar properties. This alteration has been reported in several individuals with Brugada syndrome; however, in two cases it co-occurred with other alterations in SCN5A (Núñez L et al. Heart Rhythm, 2013 Feb;10:264-72; Selga E et al. PLoS ONE, 2015 Jul;10:e0132888; Zeng Z et al. Mol Med Rep, 2016 Jun;13:5216-22). In vitro functional studies suggest this alteration results in reduced sodium current, but such studies do not always reflect function in vivo (Núñez L et al. Heart Rhythm, 2013 Feb;10:264-72; Zeng Z et al. Mol Med Rep, 2016 Jun;13:5216-22; Pérez-Hernández M et al. JCI Insight, 2018 Sep;3: pii: 96291). This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at